EMPHASIS-HF
Eplerenone in Mild Patients Hospitalisation and Survival Study in Heart Failure
Patient / Population Intervention / Exposure Comparison Outcome
In 2,737 patients with mild HFrEF (NYHA II, EF ≤ 35 %), eplerenone reduced cardiovascular death or heart-failure hospitalisation compared with placebo.
N
2,737
Design
Double-blind RCT, stopped early
Endpoint
CV death or HF hospitalisation
Relevance
2
Result18.3 % vs 25.9 % (HR 0.63).
Zannad F, et al. N Engl J Med. 2011;364(1):11-21. 10.1056/NEJMoa1009492
Discussion & critique
Extended MRA benefit from severe (RALES) to mild HF. Hyperkalaemia mandates monitoring; eplerenone avoids the gynaecomastia of spironolactone.